Novel therapies in small cell lung cancer

Hirva Mamdani, Raghava Induru, Shadia Jalal

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a tendency to metastasize widely early in the course of the disease. The VA staging system classifies the disease into limited stage (LS) which is confined to one hemithorax and can be included into one radiation field or extensive stage (ES) which extends beyond one hemithorax. Current standard of care is concurrent chemoradiation for LS disease and chemotherapy alone for ES disease. Only a quarter of patients with LS disease will be cured with current standard treatments and majority of the patients ultimately succumb to their disease. A very complex genetic landscape of SCLC accounts for its resistance to conventional therapy and a high recurrence rate, however, at the same time this complexity can form the basis for effective targeted therapy for the disease. In recent years, several different therapeutic strategies and targeted agents have been under investigation for their potential role in SCLC. Several of them including EGFR TKIs, BCR-ABL TKIs, mTOR inhibitors, and VEGF inhibitors have been unsuccessful in showing a survival advantage in this disease. Several others including DNA repair inhibitors, cellular developmental pathway inhibitors, antibody drug conjugates (ADCs), as well as immune therapy with vaccines, immunomodulators, and immune checkpoint inhibitors are being tested. So far, none of these agents are approved for use in SCLC and the majority are in phase I/II clinical trials, with immune checkpoint inhibitors being the most promising therapeutic strategy. In this article, we will discuss these novel therapeutic agents and currently available data in SCLC.

Original languageEnglish (US)
Pages (from-to)533-544
Number of pages12
JournalTranslational Lung Cancer Research
Volume4
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Small Cell Lung Carcinoma
Therapeutics
Active Immunotherapy
Phase II Clinical Trials
Clinical Trials, Phase I
Neuroendocrine Tumors
Immunologic Factors
Standard of Care
DNA Repair
Vascular Endothelial Growth Factor A
Radiation
Recurrence
Drug Therapy
Lung
Survival
Antibodies
Pharmaceutical Preparations

Keywords

  • Immune therapy
  • Molecular targeted therapy
  • Notch inhibition
  • PARP1 inhibition
  • Small cell lung cancer (SCLC)

ASJC Scopus subject areas

  • Oncology

Cite this

Novel therapies in small cell lung cancer. / Mamdani, Hirva; Induru, Raghava; Jalal, Shadia.

In: Translational Lung Cancer Research, Vol. 4, No. 5, 2015, p. 533-544.

Research output: Contribution to journalArticle

Mamdani, Hirva ; Induru, Raghava ; Jalal, Shadia. / Novel therapies in small cell lung cancer. In: Translational Lung Cancer Research. 2015 ; Vol. 4, No. 5. pp. 533-544.
@article{5f7191d8507f48648bfba660b13e4d25,
title = "Novel therapies in small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a tendency to metastasize widely early in the course of the disease. The VA staging system classifies the disease into limited stage (LS) which is confined to one hemithorax and can be included into one radiation field or extensive stage (ES) which extends beyond one hemithorax. Current standard of care is concurrent chemoradiation for LS disease and chemotherapy alone for ES disease. Only a quarter of patients with LS disease will be cured with current standard treatments and majority of the patients ultimately succumb to their disease. A very complex genetic landscape of SCLC accounts for its resistance to conventional therapy and a high recurrence rate, however, at the same time this complexity can form the basis for effective targeted therapy for the disease. In recent years, several different therapeutic strategies and targeted agents have been under investigation for their potential role in SCLC. Several of them including EGFR TKIs, BCR-ABL TKIs, mTOR inhibitors, and VEGF inhibitors have been unsuccessful in showing a survival advantage in this disease. Several others including DNA repair inhibitors, cellular developmental pathway inhibitors, antibody drug conjugates (ADCs), as well as immune therapy with vaccines, immunomodulators, and immune checkpoint inhibitors are being tested. So far, none of these agents are approved for use in SCLC and the majority are in phase I/II clinical trials, with immune checkpoint inhibitors being the most promising therapeutic strategy. In this article, we will discuss these novel therapeutic agents and currently available data in SCLC.",
keywords = "Immune therapy, Molecular targeted therapy, Notch inhibition, PARP1 inhibition, Small cell lung cancer (SCLC)",
author = "Hirva Mamdani and Raghava Induru and Shadia Jalal",
year = "2015",
doi = "10.3978/j.issn.2218-6751.2015.07.20",
language = "English (US)",
volume = "4",
pages = "533--544",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "5",

}

TY - JOUR

T1 - Novel therapies in small cell lung cancer

AU - Mamdani, Hirva

AU - Induru, Raghava

AU - Jalal, Shadia

PY - 2015

Y1 - 2015

N2 - Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a tendency to metastasize widely early in the course of the disease. The VA staging system classifies the disease into limited stage (LS) which is confined to one hemithorax and can be included into one radiation field or extensive stage (ES) which extends beyond one hemithorax. Current standard of care is concurrent chemoradiation for LS disease and chemotherapy alone for ES disease. Only a quarter of patients with LS disease will be cured with current standard treatments and majority of the patients ultimately succumb to their disease. A very complex genetic landscape of SCLC accounts for its resistance to conventional therapy and a high recurrence rate, however, at the same time this complexity can form the basis for effective targeted therapy for the disease. In recent years, several different therapeutic strategies and targeted agents have been under investigation for their potential role in SCLC. Several of them including EGFR TKIs, BCR-ABL TKIs, mTOR inhibitors, and VEGF inhibitors have been unsuccessful in showing a survival advantage in this disease. Several others including DNA repair inhibitors, cellular developmental pathway inhibitors, antibody drug conjugates (ADCs), as well as immune therapy with vaccines, immunomodulators, and immune checkpoint inhibitors are being tested. So far, none of these agents are approved for use in SCLC and the majority are in phase I/II clinical trials, with immune checkpoint inhibitors being the most promising therapeutic strategy. In this article, we will discuss these novel therapeutic agents and currently available data in SCLC.

AB - Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a tendency to metastasize widely early in the course of the disease. The VA staging system classifies the disease into limited stage (LS) which is confined to one hemithorax and can be included into one radiation field or extensive stage (ES) which extends beyond one hemithorax. Current standard of care is concurrent chemoradiation for LS disease and chemotherapy alone for ES disease. Only a quarter of patients with LS disease will be cured with current standard treatments and majority of the patients ultimately succumb to their disease. A very complex genetic landscape of SCLC accounts for its resistance to conventional therapy and a high recurrence rate, however, at the same time this complexity can form the basis for effective targeted therapy for the disease. In recent years, several different therapeutic strategies and targeted agents have been under investigation for their potential role in SCLC. Several of them including EGFR TKIs, BCR-ABL TKIs, mTOR inhibitors, and VEGF inhibitors have been unsuccessful in showing a survival advantage in this disease. Several others including DNA repair inhibitors, cellular developmental pathway inhibitors, antibody drug conjugates (ADCs), as well as immune therapy with vaccines, immunomodulators, and immune checkpoint inhibitors are being tested. So far, none of these agents are approved for use in SCLC and the majority are in phase I/II clinical trials, with immune checkpoint inhibitors being the most promising therapeutic strategy. In this article, we will discuss these novel therapeutic agents and currently available data in SCLC.

KW - Immune therapy

KW - Molecular targeted therapy

KW - Notch inhibition

KW - PARP1 inhibition

KW - Small cell lung cancer (SCLC)

UR - http://www.scopus.com/inward/record.url?scp=84960076428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960076428&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-6751.2015.07.20

DO - 10.3978/j.issn.2218-6751.2015.07.20

M3 - Article

VL - 4

SP - 533

EP - 544

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 5

ER -